Company intelligence / Profile preview

Guangzhou Baiyunshan Jingxiutang Pharmaceutical

Foshan, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Manufactures finished pharmaceuticals in China. Recently received an FDA warning letter citing significant violations of current Good Manufacturing Practice regulations during a December 2023 inspection. Issues included inadequate laboratory controls and quality unit deficiencies.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeTraditional Chinese Medicine products
Industry: Biotech

Drug pipeline

3 assets

Gu-Shen Ding-Chuan-Wan

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Guangzhou Baiyunshan Jingxiutang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Baiyunshan Jingxiutang Pharmaceutical.

Explore the full profile